Análisis

Celltrion reported Q2 revenue of 1.3 trillion KRW and operating profit of 430 billion KRW, surpassing consensus estimates, prompting analysts to lift target prices.

Sky Labs submitted its securities filing to the Financial Services Commission and began its public offering, targeting 2 million shares at KRW 13,000‑16,000 each.

Korea’s pharma/bio sector lagged the H1 market rally but fundamentals remain solid; iM Securities advises H2 investment in policy‑benefit firms, obesity treatments and ADCs, with long‑term focus on earnings‑growth companies.

Kolon Life Science will attend BIO Asia–Taiwan 2026 in Taipei (July 15‑19) to meet potential partners for TG‑C, its cell‑gene therapy for osteoarthritis, targeting the Greater China market.

CHD Pharma, formerly Cheonhye-dang, introduced Hydration ORS and electrolyte glucose candy, building on its top‑selling saline‑glucose tablets that led pharmacy orders from July 2025‑June 2026.

Fierce Pharma introduces a weekly Oral GLP‑1 Tracker using analysts’ notes and IQVIA data to track prescription trends as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo compete for the oral weight‑loss market.

Gwangdong Pharmaceutical selects webtoon artist Gi-an84 as the first brand ambassador for its new ion drink Vita500 Ion Kick, launching a promotional campaign.

Klick Health completes its third acquisition in 18 months, buying Oxford PharmaGenesis to expand globally and deepen scientific expertise.

Kimball Electronics announced plans to grow its life‑science contract manufacturing capabilities through acquisitions in Europe and India.

Following the shutdown of Erwinase’s manufacturer, Korea’s Rare & Essential Medicines Center signed a contract for Enrylaze, restoring treatment continuity for acute lymphoblastic leukemia and lymphoma patients.

Tenpoint’s new Yuvezzi consumer campaign uses handcrafted puppets to illustrate everyday blurry‑vision hassles faced by people with presbyopia.

Roche tops PatientView’s oncology reputation ranking, with AstraZeneca climbing to second thanks to breast and lung cancer strengths.